<DOC>
	<DOCNO>NCT00450229</DOCNO>
	<brief_summary>Giving diindolylmethane , substance find cruciferous vegetable , may help doctor learn diindolylmethane use body . This randomized phase I trial study side effect best dose diindolylmethane compare placebo treat patient undergo radical prostatectomy stage I stage II prostate cancer .</brief_summary>
	<brief_title>Diindolylmethane Treating Patients Undergoing Surgery Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare neoadjuvant prostatic diindolylmethane ( DIM^ ) concentration patient stage I II adenocarcinoma prostate treat DIM v placebo prior radical prostatectomy . SECONDARY OBJECTIVES : I . Compare ratio urinary 2-hydroxyestrone:16-hydroxyestrone patient treated regimen . II . Compare plasma level total prostate-specific antigen ( PSA ) patient treat regimen . III . Compare serum testosterone level patient treat regimen . IV . Compare ratio plasma insulin-like growth factor ( IGF ) -1 : IGF bind protein-3 patient treat regimen . V. Compare cytochrome p450 mRNA expression CYP1A1 , CYP1A2 , CYP2B1 , CYP3A enzymes circulate polymorphonuclear leukocyte ( PMNs ) fresh frozen tissue patient treat regimen . VI . Compare DIM blood steady-state concentration patient treat regimen . VII . Identify polymorphisms CYP1A1 , CYP1A2 , CYP2B1 , CYP3A circulate PMNs patient treat regimen . VIII . Compare tissue level PSA , androgen receptor , Ki-67 , caspase 3 patient treated regimen . OUTLINE : This randomize , placebo-controlled , multicenter study . Patients randomize 1 3 treatment arm . Arm I : Patients receive low-dose , nutritional-grade oral diindolylmethane ( DIM ) twice daily 21-28 day absence disease progression unacceptable toxicity . Treatment may continue 60 day , surgery delayed . Arm II : Patients receive high-dose , nutritional-grade oral DIM twice daily arm I . Arm III : Patients receive oral placebo twice daily 21-28 day absence disease progression unacceptable toxicity . Treatment may continue 60 day , surgery delayed . Patients arm undergo surgical resection tumor within 1 day completion DIM placebo . Patients undergo blood , tissue , urine sample collection periodically study immunohistochemical ( IHC ) /molecular analysis pharmacokinetic pharmacogenomic correlative study . Patient specimen assess DIM level plasma tissue ( liquid chromatography/mass spectrometry [ LC/MS ] ) biologic response DIM ( TUNEL assay ) . Intermediate biomarkers DIM activity also assess , include urinary 2-hydroxyestrone:16-hydroxyestrone ratio ( LC/MS assay ) , plasma total prostate-specific antigen ( PSA ) , plasma insulin-like growth factor ( IGF ) -1 : IGF bind protein-3 ratio ( ELISA ) , tissue androgen receptor , PSA , Ki-67 , caspase 3 ( immunohistochemistry ) . Cytochrome p450 induction gene expression ( CYP1A1 , CYP1A2 , CYP2B1 , CYP3A ) also assess tissue plasma semiquantitative real-time polymerase chain reaction .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Criteria : Histologically confirm adenocarcinoma prostate Clinical stage T1 T2 , b , c ( stage III disease ) Disease confine within prostate gland Candidate radical prostatectomy ECOG performance status ( PS ) 01 OR Karnofsky PS 80100 % WBC normal Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 10 g/dL AST = &lt; 1.5 time upper limit normal Creatinine = &lt; 2.0 mg/dL Fertile patient must use effective contraception No history allergic reaction attribute diindolylmethane ( DIM^ ) , inactive ingredient contain BioResponseDIM^NG placebo , compound similar chemical biologic composition No concurrent uncontrolled illness include , limited , follow : Ongoing active infection , Symptomatic congestive heart failure , Unstable angina pectoris , Cardiac arrhythmia , No psychiatric illness social situation would preclude study compliance No prior chemotherapy , hormonal therapy , brachytherapy , external radiotherapy prostate cancer No concurrent nonsteroidal antiinflammatory drug , include acetylsalicylic acid , ibuprofen , naproxen sodium , cyclooxygenase2 inhibitor No concurrent systemic therapy cancer No concurrent investigational agent No concurrent p450 inducer inhibitor , include follow : Carbamazepine , Clarithromycin , Fluconazole , Fosphenytoin , Itraconazole , Ketoconazole , Phenobarbital , Phenytoin , Rifabutin , Rifampin No concurrent finasteride dutasteride No 1 serve cruciferous vegetable per day duration study Cruciferous vegetable include follow : broccoli , cauliflower , brussels sprout , cabbage , arugula , watercress , bokchoy , turnip green , mustard green , collard green , rutabaga , Napa Chinese cabbage , radish , turnip , kohlrabi , kale Bilirubin normal At least 21 day since prior surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>